Skip to content

Performance Evaluation cobas click for HbA1c and Lipid panel

Performance Evaluation cobas click for HbA1c and Lipid panel - Cobas click

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
NL-OMON
Registry ID
NL-OMON53795
Enrollment
360
Registered
2023-06-28
Start date
2024-04-19
Completion date
Unknown
Last updated
2025-09-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes mellitus (person with high glucose level) and dyslipidemia (imbalance of lipids)

Interventions

None listed

Sponsors

Roche Diagnostics International Ltd
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Informed consent signed. Subject is >= 18 years old at the time of enrollment.

Exclusion criteria

Exclusion criteria: Subjects for whom informed consent is not signed before sample collection. Subjects whom the attending physician has determined that the health status of the subject is at risk and/or may be compromised if a blood draw is performed. Subjects who have received an intravenous lipid emulsion injection within 5 days of the study blood draw. Pregnant subjects.

Design outcomes

Primary

MeasureTime frame
- Method comparison between HbA1c and Lipid panel test: capillary vs venous whole blood (EDTA K2 and K3) on cobas click system vs. laboratory reference equipment. - Method comparison between HbA1c and Lipid panel test: capillary vs venous whole blood (EDTA K2 and K3) on cobas b 101/alpha software vs. laboratory reference equipment. Method comparison acceptance criteria for HbA1c: -Slope: 1.000±0.060 -Intercept: =0.980 Bias on medical decision points: On 5.0% HbA1c: =0.975 Intercept: Total Cholesterol:

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)